ENTITY
Xiamen Amoytop Biotech Co Ltd

Xiamen Amoytop Biotech Co Ltd (688278 CH)

19
Analysis
Health Care • China
Xiamen Amoytop Biotech Co., Ltd. operates as a drug development company. The Company develops and sells protein drugs, interferon drugs, and other products. Xiamen Amoytop Biotech markets its products primarily throughout China with limited overseas.
more
•22 Sep 2024 06:04

Quiddity Leaderboard STAR 50/100 Dec 24: STAR 50 Exp ADD Could Outperform STAR 50 Exp DEL

The expected STAR 50 ADD and DEL could see net index buying of 14x ADV and net index selling of 8x ADV respectively during the STAR 50/100 index...

Share
bearish•VISEN Pharmaceuticals
•19 Oct 2023 08:55

Pre-IPO VISEN Pharmaceuticals - The Product Pipeline and the Key Risks

VISEN’s pipeline has strength, but fierce competition/VBP/increasingly stringent regulatory environment will bring challenges to...

Logo
670 Views
Share
•27 Nov 2021 10:38

STAR50 Index Rebalance: Oops! They Did It Again...

There are 5 changes at the Dec rebalance as the index committee have continued to use a 6 month minimum listing history even though the methodology...

Logo
615 Views
Share
bullish•GoodWe Technologies
•15 Oct 2021 07:30

STAR50 Index Rebalance Dec 21 Preview: Big Turnover & Moderate Impact

We see 5 potential changes to the STAR50 index in Dec and expect a 12 month minimum listing history to be used. The potential inclusions should...

Logo
553 Views
Share
•08 Sep 2021 10:33

STAR50 Index Rebalance December Preview: 12 Month or 6 Month Listing History, That Is The Question

CSI and SSE could start to use a 12 month minimum listing history requirement from the December rebalance. One-way turnover could be in excess of...

Logo
434 Views
Share
x